Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) Profit After Tax (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Profit After Tax for 9 consecutive years, with -$6.8 million as the latest value for Q4 2024.

  • On a quarterly basis, Profit After Tax rose 16.96% to -$6.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$30.9 million, a 17.25% increase, with the full-year FY2024 number at -$30.9 million, up 17.25% from a year prior.
  • Profit After Tax was -$6.8 million for Q4 2024 at SELLAS Life Sciences, up from -$7.1 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$2.4 million in Q1 2021 to a low of -$16.7 million in Q1 2022.
  • A 5-year average of -$7.3 million and a median of -$7.1 million in 2021 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: surged 49.91% in 2020, then plummeted 596.8% in 2022.
  • SELLAS Life Sciences' Profit After Tax stood at -$3.7 million in 2020, then tumbled by 77.58% to -$6.6 million in 2021, then tumbled by 38.22% to -$9.1 million in 2022, then increased by 10.8% to -$8.1 million in 2023, then grew by 16.96% to -$6.8 million in 2024.
  • Per Business Quant, the three most recent readings for SLS's Profit After Tax are -$6.8 million (Q4 2024), -$7.1 million (Q3 2024), and -$7.5 million (Q2 2024).